Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

NCT00795639 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

183

Enrollment

INDUSTRY

Sponsor class

Stopped Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.

Conditions

Pulmonary Arterial Hypertension
Pulmonary Hypertension

Interventions

DRUG: Sitaxsentan
DRUG: Placebo

Sponsor

Pfizer